Shanghai Gynecologic Oncology Group is the lead sponsor of 9 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Bevacizumab, Iparomlimab and Tuvonralimab and Niraparib. The most-studied condition is Primary Peritoneal Carcinoma.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Drug: Bevacizumab |
Phase 2 | Recruiting | 2022-07 | China |
|
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT03983226 · ClinicalTrials.gov ↗ · Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Drug: Niraparib |
Phase 2 | Recruiting | 2019-10 | China |
|
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NCT05236686 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
|
Not applicable | Recruiting | 2022-02 | China |
|
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
NCT07674615 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary
Drug: Sacituzumab Govitecan |
Phase 1 | Not yet open | 2026-07 | China |
|
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
NCT04515602 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
|
Phase 3 | Not yet open | 2021-01 | China |
|
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
NCT06846424 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
|
Phase 1 | Not yet open | 2025-06 | China |
|
Surgery for Relapsed Ovarian Cancer in Precision
NCT06602063 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
|
Phase 1/2 | Not yet open | 2025-07 | China |
|
O-RADS MRI System on Early Detection of Ovarian Cancer
NCT07009743 · ClinicalTrials.gov ↗ · Ovarian Cancer (OvCa), Ovarian Cancer Metastatic
|
Observational | Active, closed | 2025-01 | China |
|
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT02859038 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
|
Phase 3 | Active, closed | 2016-08 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 3 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Beijing Biotech | 2 |
Sponsors with the most current trials registered for this condition.
Shanghai Gynecologic Oncology Group is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 4 drugs and biologicals as interventions. The most frequent are Bevacizumab (1), Iparomlimab and Tuvonralimab (1), Niraparib (1) and Sacituzumab Govitecan (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.